Authors
Nicole J Hardy, Alicia Mitchell, Jeffrey M Cohen, Gabriela Cobos, Hao Feng
Published in
Clinics in dermatology. Nov 20, 2026. Epub Nov 20, 2026.
Abstract
Type I cryoglobulinemia is a rare disorder characterized by the precipitation of monoclonal immunoglobulins in cold temperatures, leading to hyperviscosity and vaso-occlusion and associated with cutaneous manifestations in 44% of the patients. This review explores the epidemiology, pathophysiology, clinical presentation, diagnosis, treatment, and prognosis of Type I cryoglobulinemia with data from recent cohort studies obtained via a systematic review (CRD42024592479) using PubMed and Scopus databases. Inclusion criteria encompassed studies on Type I cryoglobulinemia with a focus on dermatological manifestations and a minimum sample size of ten patients. Thirteen retrospective cohort studies involving 794 patients were included. Our review demonstrated that Type I cryoglobulinemia accounts for at least 10-15% of cryoglobulinemia cases, with monoclonal IgM and IgG as the predominant immunoglobulin isotypes. Most cases are associated with hematological malignancies such as MGUS (31%), Waldenström macroglobulinemia (27%), and non-Hodgkin lymphoma (20%). Cutaneous manifestations included purpura, ulcers, and necrosis and were more severe with IgG-associated lesions. Neurological and renal involvement occurred in 25% and 24% of patients, respectively. Bortezomib and rituximab-based regimens showed efficacy, but relapses were common. While survival rates were nearly 100% at 1-year, the 10-year survival rates were lower and ranged from 52.5-87%.
PMID:
43064036
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0